Rocket Pharmaceuticals (RCKT) Operating Expenses (2014 - 2026)

Rocket Pharmaceuticals has reported Operating Expenses for 13 years, with the latest figure at $48.5 million in Q1 2026.

• Quarterly Operating Expenses fell 24.66% year-over-year to $48.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $215.9 million (down 20.11% YoY) and the FY2025 annual result came in at $231.7 million, down 15.17% from the prior year.
• Operating Expenses climbed to $48.5 million in Q1 2026 per RCKT's latest filing, from $44.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $73.7 million in Q2 2024 and troughed at $42.6 million in Q1 2022.
• A 5-year average of $61.0 million and a median of $63.3 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 59.22% in 2022, then decreased 29.88% in 2025.
• Over 5 years, Operating Expenses stood at $69.1 million in 2022, then retreated by 8.4% to $63.3 million in 2023, then decreased by 0.92% to $62.7 million in 2024, then fell by 29.88% to $44.0 million in 2025, then gained by 10.35% to $48.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $48.5 million, $44.0 million, and $52.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.